The role of carbonic anhydrase IX in hypoxia control in OSCC

Journal of Oral Pathology and Medicine

Volumn 42, Issue 1, 2013, Pages 1-8

  Pérez Sayáns, Mario ^a   Supuran, Claudiu T ^b   Pastorekova, Silvia ^c   Suárez Peñaranda, José Manuel ^d   Pilar, Gayoso Diz ^a,d   Barros Angueira, Francisco ^d   Gándara Rey, José Manuel ^e   García García, Abel ^a  

^a Santiago University Clinical Hospital   (Spain)

^b UNIVERSITY OF FLORENCE   (Italy)

^c INSTITUTE OF VIROLOGY   (Slovakia)

^d Instituto de Salud Carlos III   (Spain)

^e UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

CA IX; Carbonic anhydrases; Hypoxia; Oral squamous cell carcinoma

Indexed keywords

CARBONATE DEHYDRATASE IX; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KI 67 ANTIGEN; NIMORAZOLE;

ANGIOGENESIS; CHEMOSENSITIVITY; HUMAN; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIOSENSITIVITY; REVIEW;

ANOXIA; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CARBONIC ANHYDRASES; CARCINOMA, SQUAMOUS CELL; DRUG RESISTANCE, NEOPLASM; ERYTHROPOIETIN; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE TRANSPORTER TYPE 1; HEAD AND NECK NEOPLASMS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KI-67 ANTIGEN; MOUTH NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RADIATION TOLERANCE; RECEPTORS, ERYTHROPOIETIN;

EID: 84871933899     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2012.01144.x     Document Type: Review

References (80)

1. Vaupel P, Mayer A, Hockel M. Tumor hypoxia and malignant progression. Methods Enzymol 2004; 381: 335-54.
2. Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist 2004; 9(Suppl 5): 10-7.
3. Osinsky S, Zavelevich M, Vaupel P. Tumor hypoxia and malignant progression. Exp Oncol 2009; 31: 80-6.
4. Vaupel P. Metabolic microenvironment of tumor cells: a key factor in malignant progression. Exp Oncol 2010; 32: 125-7.
5. Le QT. Identifying and targeting hypoxia in head and neck cancer: a brief overview of current approaches. Int J Radiat Oncol Biol Phys 2007; 2(Suppl): S56-8.
6. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2: 38-47.
7. Le QT, Denko NC, Giaccia AJ. Hypoxic gene expression and metastasis. Cancer Metastasis Rev 2004; 23: 293-310.
8. Vigneswaran N, Wu J, Song A, Annapragada A, Zacharias W. Hypoxia-induced autophagic response is associated with aggressive phenotype and elevated incidence of metastasis in orthotopic immunocompetent murine models of head and neck squamous cell carcinomas (HNSCC). Exp Mol Pathol 2011; 90: 215-25.
9. Graeber TG, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996; 379: 88-91.
10. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001; 93: 266-76.
11. Vaupel P, Thews O, Hoeckel M. Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol 2001; 18: 243-59.
12. Dewhirst MW, Ong ET, Braun RD, et al. Quantification of longitudinal tissue pO2 gradients in window chamber tumours: impact on tumour hypoxia. Br J Cancer 1999; 79: 1717-22.
13. Lutterbach J, Guttenberger R. Anemia is associated with decreased local control of surgically treated squamous cell carcinomas of the glottic larynx. Int J Radiat Oncol Biol Phys 2000; 48: 1345-50.
14. Petersen C, Zips D, Krause M, et al. Repopulation of FaDu human squamous cell carcinoma during fractionated radiotherapy correlates with reoxygenation. Int J Radiat Oncol Biol Phys 2001; 51: 483-93.
15. Overgaard J, Hansen HS, Specht L, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 2003; 362: 933-40.
16. Hoogsteen IJ, Marres HA, Bussink J, Van der Kogel AJ, Kaanders JH. Tumor microenvironment in head and neck squamous cell carcinomas: predictive value and clinical relevance of hypoxic markers. A review. Head Neck 2007; 29: 591-604.
17. Hoogsteen IJ, Marres HA, Wijffels KI, et al. Colocalization of carbonic anhydrase 9 expression and cell proliferation in human head and neck squamous cell carcinoma. Clin Cancer Res 2005; 11: 97-106.
18. Evans SM, Hahn S, Pook DR, et al. Detection of hypoxia in human squamous cell carcinoma by EF5 binding. Cancer Res 2000; 60: 2018-24.
19. Raleigh JA, Calkins-Adams DP, Rinker LH, et al. Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. Cancer Res 1998; 58: 3765-8.
20. Gleadle JM, Ratcliffe PJ. Hypoxia and the regulation of gene expression. Mol Med Today 1998; 4: 122-9.
21. Perez-Sayans M, Suarez-Penaranda JM, Pilar GD, Barros-Angueira F, Gandara-Rey JM, Garcia-Garcia A. Hypoxia-inducible factors in OSCC. Cancer Lett 2011; 313: 1-8.
22. Gnarra JR, Zhou S, Merrill MJ, et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci U S A 1996; 93: 10589-94.
23. Lal A, Peters H, St Croix B, et al. Transcriptional response to hypoxia in human tumors. J Natl Cancer Inst 2001; 93: 1337-43.
24. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
25. Supuran CT. Carbonic anhydrase inhibitors and activators for novel therapeutic applications. Future Med Chem 2011; 3: 1165-80.
26. Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 2011; 10: 767-77.
27. Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008; 7: 168-81.
28. Supuran CT. Carbonic anhydrase inhibitors. Bioorg Med Chem Lett 2010; 20: 3467-74.
29. Vullo D, Franchi M, Gallori E, et al. Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides. Bioorg Med Chem Lett 2003; 13: 1005-9.
30. Vullo D, Innocenti A, Nishimori I, et al. Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglaucoma drugs?. Bioorg Med Chem Lett 2005; 15: 963-9.
31. Ivanov S, Liao SY, Ivanova A, et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 2001; 158: 905-19.
32. Bussink J, Kaanders JH, van der Kogel AJ. Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiother Oncol 2003; 67: 3-15.
33. Brewer CA, Liao SY, Wilczynski SP, et al. A study of biomarkers in cervical carcinoma and clinical correlation of the novel biomarker MN. Gynecol Oncol 1996; 63: 337-44.
34. Giatromanolaki A, Koukourakis MI, Sivridis E, et al. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res 2001; 61: 7992-8.
35. Klatte T, Belldegrun AS, Pantuck AJ. The role of carbonic anhydrase IX as a molecular marker for transitional cell carcinoma of the bladder. BJU Int 2008; 101(Suppl 4): 45-8.
36. Chia SK, Wykoff CC, Watson PH, et al. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol 2001; 19: 3660-8.
37. Turner JR, Odze RD, Crum CP, Resnick MB. MN antigen expression in normal, preneoplastic, and neoplastic esophagus: a clinicopathological study of a new cancer-associated biomarker. Hum Pathol 1997; 28: 740-4.
38. Saarnio J, Parkkila S, Parkkila AK, et al. Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA-IX, with potential value as a marker of cell proliferation. Am J Pathol 1998; 153: 279-85.
39. Perez-Sayans M, Somoza-Martin JM, Barros-Angueira F, Reboiras-Lopez MD, Gandara Rey JM, Garcia-Garcia A. Genetic and molecular alterations associated with oral squamous cell cancer (Review). Oncol Rep 2009; 22: 1277-82.
40. Choi SW, Kim JY, Park JY, Cha IH, Kim J, Lee S. Expression of carbonic anhydrase IX is associated with postoperative recurrence and poor prognosis in surgically treated oral squamous cell carcinoma. Hum Pathol 2008; 39: 1317-22.
41. Roh JL, Cho KJ, Kwon GY, et al. The prognostic value of hypoxia markers in T2-staged oral tongue cancer. Oral Oncol 2009; 45: 63-8.
42. Oliveira LR, Ribeiro-Silva A. Prognostic significance of immunohistochemical biomarkers in oral squamous cell carcinoma. Int J Oral Maxillofac Surg 2011; 40: 298-307.
43. Eckert AW, Lautner MH, Schutze A, Taubert H, Schubert J, Bilkenroth U. Coexpression of hypoxia-inducible factor-1alpha and glucose transporter-1 is associated with poor prognosis in oral squamous cell carcinoma patients. Histopathology 2011; 58: 1136-47.
44. Kondo Y, Yoshikawa K, Omura Y, et al. Clinicopathological significance of carbonic anhydrase 9, glucose transporter-1, Ki-67 and p53 expression in oral squamous cell carcinoma. Oncol Rep 2011; 25: 1227-33.
45. Eckert AW, Lautner MH, Schutze A, et al. Co-expression of Hif1alpha and CA-IX is associated with poor prognosis in oral squamous cell carcinoma patients. J Oral Pathol Med 2010; 39: 313-7.
46. Kim SJ, Shin HJ, Jung KY, et al. Prognostic value of carbonic anhydrase IX and Ki-67 expression in squamous cell carcinoma of the tongue. Jpn J Clin Oncol 2007; 37: 812-9.
47. Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res 2001; 7: 3399-403.
48. Le QT, Kong C, Lavori PW, et al. Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2007; 69: 167-75.
49. Kaanders JH, Wijffels KI, Marres HA, et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 2002; 62: 7066-74.
50. Ragin CC, Taioli E. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer 2007; 121: 1813-20.
51. Brockton N, Dort J, Lau H, et al. High stromal carbonic anhydrase IX expression is associated with decreased survival in P16-negative head-and-neck tumors. Int J Radiat Oncol Biol Phys 2011; 80: 249-57.
52. Kong CS, Narasimhan B, Cao H, et al. The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2009; 74: 553-61.
53. Jonathan RA, Wijffels KI, Peeters W, et al. The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON. Radiother Oncol 2006; 79: 288-97.
54. Beasley NJ, Wykoff CC, Watson PH, et al. Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res 2001; 61: 5262-7.
55. Bhattacharya A, Toth K, Mazurchuk R, et al. Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy. Clin Cancer Res 2004; 10: 8005-17.
56. Bhattacharya A, Toth K, Durrani FA, et al. Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts. Neoplasia 2008; 10: 857-65.
57. Chintala S, Toth K, Cao S, et al. Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha. Cancer Chemother Pharmacol 2010; 66: 899-911.
58. Zheng G, Zhou M, Ou X, et al. Identification of carbonic anhydrase 9 as a contributor to pingyangmycin-induced drug resistance in human tongue cancer cells. FEBS J 2010; 277: 4506-18.
59. Schmitt A, Barth TF, Beyer E, et al. The tumor antigens RHAMM and G250/CA-IX are expressed in head and neck squamous cell carcinomas and elicit specific CD8+ T cell responses. Int J Oncol 2009; 34: 629-39.
60. Eriksen JG, Overgaard J, Danish Head; Neck Cancer Study Group (DAHANCA). Lack of prognostic and predictive value of CA-IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: an evaluation of the DAHANCA 5 study. Radiother Oncol 2007; 83: 383-8.
61. Koukourakis MI, Bentzen SM, Giatromanolaki A, et al. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 2006; 24: 727-35.
62. Sutter CH, Laughner E, Semenza GL. Hypoxia-inducible factor 1alpha protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations. Proc Natl Acad Sci U S A 2000; 97: 4748-53.
63. Semenza GL, Rue EA, Iyer NV, Pang MG, Kearns WG. Assignment of the hypoxia-inducible factor 1alpha gene to a region of conserved synteny on mouse chromosome 12 and human chromosome 14q. Genomics 1996; 34: 437-9.
64. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003; 9: 677-84.
65. Semenza GL. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 1999; 15: 551-78.
66. Sasabe E, Tatemoto Y, Li D, Yamamoto T, Osaki T. Mechanism of HIF-1alpha-dependent suppression of hypoxia-induced apoptosis in squamous cell carcinoma cells. Cancer Sci 2005; 96: 394-402.
67. Zhu GQ, Tang YL, Li L, et al. Hypoxia inducible factor 1alpha and hypoxia inducible factor 2alpha play distinct and functionally overlapping roles in oral squamous cell carcinoma. Clin Cancer Res 2010; 16: 4732-41.
68. Winter SC, Shah KA, Han C, et al. The relation between hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression with anemia and outcome in surgically treated head and neck cancer. Cancer 2006; 107: 757-66.
69. De Schutter H, Landuyt W, Verbeken E, Goethals L, Hermans R, Nuyts S. The prognostic value of the hypoxia markers CA-IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/-chemotherapy. BMC Cancer 2005; 5: 42.
70. Winter SC, Shah KA, Campo L, et al. Relation of erythropoietin and erythropoietin receptor expression to hypoxia and anemia in head and neck squamous cell carcinoma. Clin Cancer Res 2005; 11: 7614-20.
71. Le QT, Shi G, Cao H, et al. Galectin-1: a link between tumor hypoxia and tumor immune privilege. J Clin Oncol 2005; 23: 8932-41.
72. Silva P, Slevin NJ, Sloan P, et al. Use of multiple biological markers in radiotherapy-treated head and neck cancer. J Laryngol Otol 2010; 124: 650-8.
73. Gee HE, Camps C, Buffa FM, et al. Hsa-Mir-210 is a Marker of Tumor Hypoxia and a Prognostic Factor in Head and Neck Cancer. Cancer 2010; 116: 2148-58.
74. De SchutterH, Barbe B, Spaepen M, et al. Microsatellite alterations in head and neck squamous cell carcinoma and relation to expression of pimonidazole, CA-IX and GLUT-1. Radiother Oncol 2006; 80: 143.
75. Supuran CT, Scozzafava A, Casini A. Carbonic anhydrase inhibitors. Med Res Rev 2003; 23: 146-89.
76. Lou Y, McDonald PC, Oloumi A, et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res 2011; 71: 3364-76.
77. Pacchiano F, Carta F, McDonald PC, et al. Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. J Med Chem 2011; 54: 1896-902.
78. Zatovicova M, Jelenska L, Hulikova A, et al. Carbonic anhydrase IX as an anticancer therapy target: preclinical evaluation of internalizing monoclonal antibody directed to catalytic domain. Curr Pharm Des 2010; 16: 3255-63.
79. Chrastina A, Závada J, Parkkila S, et al. Biodistribution and pharmacokinetics of 125I-labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma. Int J Cancer 2003; 105: 873-81.
80. ®) and interferon-alpha-2a in metastatic renal cell carcinoma patients. World J Urol 2011; 29: 121-6.